Q&A // CITED
Ipamorelin Questions, Answered Short
Twenty-two questions. Direct answers first, the study second.
What is ipamorelin?
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and a selective growth hormone secretagogue. It binds the ghrelin receptor (GHS-R1a) to release a pulse of growth hormone, and in its founding study it did so potently without raising cortisol or prolactin even far above its GH threshold [1]. It is not an approved drug.
What does ipamorelin do for you?
In the research, it triggers a short pulse of growth hormone by activating the ghrelin receptor, while leaving cortisol and prolactin flat [1]. Community reports describe sleep and recovery effects, but those are anecdotal. The one human efficacy trial (for postoperative ileus) failed [3]. No approved benefit is established.
What is ipamorelin peptide?
A wholly synthetic five-amino-acid peptide — a pentapeptide — derived from GHRP-1 and acting as a ghrelin / GHS-R1a receptor agonist [1]. Formula C38H49N9O5, about 711.9 Da, CAS 170851-70-4. It mimics the hunger hormone ghrelin at the pituitary to release growth hormone. It is sold only as a research chemical.
How does CJC-1295 ipamorelin work?
The combination pushes growth hormone through two separate doors. Ipamorelin activates the ghrelin receptor (GHS-R1a) [1]; CJC-1295 is a GHRH analog acting on the GHRH receptor. Two independent mechanisms, one shared GH pulse — the rationale for pairing them. No controlled human trial has tested the combination for any outcome.
Is ipamorelin selective for growth hormone?
Yes — that is its defining feature. In the 1998 founding study it released GH about as potently as GHRP-6 (swine ED50 2.3 vs 3.9 nmol/kg) but did not raise ACTH or cortisol above the GHRH baseline, even at doses more than 200-fold over the GH ED50 [1]. Prolactin was unaffected.
What are the risks of ipamorelin?
The documented risks are gaps and class signals: no long-term human safety data, a failed efficacy trial [3], a class-level cardiotoxicity signal from a related GHS-R1a agonist in rats [6], and theoretical GH/IGF-1 concerns for proliferative conditions [1][4]. Most marketed material is unregulated research-grade. See the cautions on Ipamorelin effects.
Does ipamorelin reduce belly fat?
No human trial shows that. The freshest data is a 2024 ferret study where ipamorelin reduced chemotherapy-driven body-weight loss by about 24% — weight protection, not fat loss [5]. Some animal work shows GH-independent changes in adiposity [14]. Community reports of a leaner look are anecdotal and confounded by diet and training.
What are the downsides of ipamorelin?
The hard downside is the evidence: the one human efficacy trial missed its primary endpoint (25.3 h vs 32.6 h, p=0.15) [3], and there is no long-term human safety record. Reported short-term downsides — flushing, appetite, mild fluid retention — are anecdotal. A class-level cardiac signal exists in animals [6].
Why is ipamorelin being discontinued?
It was never marketed, so there is nothing to discontinue. Clinical development reached Phase 2 for postoperative ileus and stopped when that trial missed its primary endpoint [3]. In 2024 the FDA also removed ipamorelin acetate from Category 2 of the interim 503A bulk-substances list, tightening compounding-pharmacy access.
What does CJC-1295 and ipamorelin do?
Together they amplify a growth-hormone pulse through two receptors at once: ipamorelin on the ghrelin receptor (GHS-R1a) [1] and CJC-1295 on the GHRH receptor. The aim of the pairing is a larger, complementary GH release. No combination trial supports any specific outcome; the rationale is single-agent pharmacology only.
Does ipamorelin increase IGF-1?
Not reliably in short studies. Growth hormone normally drives liver IGF-1, but the 15-day rat bone-growth study found dose-dependent bone growth with no change in total IGF-1 [4]. IGF-1 elevation appears context- and duration-dependent and is not a consistent finding in short rodent ipamorelin work.
How much CJC-1295 ipamorelin should I take?
This site gives no dose. There is no established or approved human dose for ipamorelin [3], and the CJC-1295 + ipamorelin combination was never tested as a product in a controlled human trial. The subcutaneous regimens shared in forums are community practice — anecdotal and unverified, not a recommendation.
Does CJC-1295 ipamorelin work?
For pure ipamorelin, the only human efficacy trial failed [3]. For the CJC-1295 + ipamorelin combination specifically, there is no controlled human outcome trial — its case rests on the separate pharmacology of a ghrelin mimetic and a GHRH analog, not on tested combination data.
How to reconstitute CJC-1295 ipamorelin 5mg?
This is a research-handling question and this site gives no preparation method. For context: ipamorelin is supplied as a lyophilized powder and, per the research-supply literature, reconstituted with bacteriostatic water for handling; as a peptide it is kept refrigerated and protected from heat and freeze-thaw. That is general handling context, not an instruction or a dose.
How long does ipamorelin stay in your system?
Not long. The terminal half-life in humans is about 2 hours (IV), with the GH response a single pulse peaking near 40 minutes [2]. Clearance is 0.078 L/h/kg and the distribution volume 0.22 L/kg [2]. The action is short and self-limiting rather than sustained.
Does ipamorelin make you hungry?
It can, mechanistically. Ipamorelin acts on the ghrelin ("hunger hormone") receptor, and central GH-secretagogue administration induces feeding in rats [10]. Community reports describe increased appetite after dosing, generally milder than with GHRP-6 [1]. A 2026 review notes appetite effects among the class's known actions.
Will I gain weight on ipamorelin?
Animal data point to weight change via GH-axis and GH-independent routes — an ipamorelin-derived oral analog raised rat body weight over 14 days [8], and ipamorelin raised adiposity in mice independently of GH [14]. In humans there is no controlled body-composition data; the one human efficacy trial was for ileus, not weight [3].
Does ipamorelin increase appetite?
Mechanistically yes — it is a ghrelin-receptor agonist, and ghrelin-receptor activation switches on hypothalamic appetite centers and induces feeding in rats [10]. A 2026 critical review lists appetite effects among the class's actions. Community reports describe this as real but generally milder than older GHRPs.
What does ipamorelin peptide do?
It activates the ghrelin receptor (GHS-R1a) on the pituitary to release a pulse of growth hormone, selectively — without raising cortisol or prolactin [1]. The pulse peaks near 40 minutes and clears within hours [2]. Beyond that, reported effects (sleep, recovery) are anecdotal, and no human efficacy is established [3].
How long does it take for ipamorelin to work?
Pharmacologically, fast: the GH pulse peaks about 40 minutes after an IV dose and the half-life is roughly 2 hours [2]. That is the measured hormonal response. Any subjective effects people describe (such as sleep changes within a week or two) are anecdotal and not established in trials.
Does ipamorelin cause water retention?
Possibly, by mechanism. Growth-hormone excess is associated with sodium and water retention, and community reports describe mild, transient puffiness early on, generally milder than with older GHRPs. There is no controlled human study of fluid balance on ipamorelin; the failed Phase 2 trial assessed bowel recovery, not edema [3].
Where to inject CJC-1295 ipamorelin?
This site gives no administration instruction. In research and community use the dominant route is subcutaneous (under the skin), while the human trials used the intravenous route [2][3]. That describes routes studied or reported — it is not a how-to, a site recommendation, or a dose.